Regenxbio (RGNX) Misses Q4 EPS by 14c

Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.38), $0.14 worse than the analyst estimate of ($1.24). Revenue for the quarter came in at $31.35 million versus the consensus estimate of $39.41 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'